Profile data is unavailable for this security.
About the company
Wanbury Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical and related activities, including research. The Company operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. It has approximately 13 API products. It manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The Company's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).
- Revenue in INR (TTM)5.69bn
- Net income in INR233.39m
- Incorporated1988
- Employees1.58k
- LocationWanbury Ltd'B' Wing, 10th Floor, BSEL TechparkOpp. Vashi Railway Station, Sector 30AVashiNAVI MUMBAI 400703IndiaIND
- Phone+91 2 267942222
- Fax+91 2 267942111
- Websitehttp://www.wanbury.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medico Remedies Ltd | 1.32bn | 69.58m | 3.78bn | -- | 54.71 | -- | 38.47 | 2.87 | 0.8326 | 0.8326 | 15.75 | -- | -- | -- | -- | -- | -- | 4.76 | -- | 10.00 | 24.15 | 24.40 | 5.29 | 3.14 | -- | 11.07 | -- | -- | 16.04 | 18.14 | 48.09 | 42.78 | 52.68 | -- |
| Lyka Labs Ltd | 1.06bn | -35.60m | 4.24bn | 713.00 | -- | -- | 43.07 | 4.01 | -1.23 | -1.23 | 33.69 | -- | -- | -- | -- | -- | -- | -5.48 | -- | -9.31 | 61.37 | 59.75 | -3.34 | -10.63 | -- | 0.5422 | -- | -- | -52.05 | 8.95 | -133.88 | -- | 17.78 | -- |
| Venus Remedies Ltd. | 5.62bn | 290.26m | 4.26bn | 998.00 | 14.68 | -- | 7.37 | 0.759 | 21.73 | 21.73 | 420.31 | -- | -- | -- | -- | 5,630,556.00 | -- | 2.84 | -- | 3.84 | 42.76 | 39.68 | 5.17 | 3.83 | -- | 559.36 | -- | -- | -7.21 | 8.33 | -34.77 | -- | -10.05 | -- |
| Wanbury Ltd | 5.69bn | 233.39m | 4.89bn | 1.58k | 20.95 | -- | 13.51 | 0.8583 | 7.12 | 7.12 | 173.80 | -- | -- | -- | -- | 3,598,099.00 | -- | 6.56 | -- | -- | 46.15 | 43.92 | 4.10 | 4.54 | -- | 1.82 | -- | -- | -2.26 | 5.95 | -112.76 | -- | 34.73 | -- |
| Kilitch Drugs (India) Ltd | 1.55bn | 145.71m | 5.71bn | 153.00 | 38.55 | -- | 35.41 | 3.68 | 9.21 | 9.21 | 98.24 | -- | -- | -- | -- | 10,132,730.00 | -- | 2.63 | -- | 3.59 | 39.68 | 33.85 | 8.25 | 5.01 | -- | 3.43 | -- | 2.93 | 22.20 | 22.30 | 41.82 | 15.19 | 1.79 | -- |
| ZIM Laboratories Ltd | 3.55bn | 163.97m | 5.83bn | 525.00 | 35.60 | -- | 17.47 | 1.64 | 3.36 | 3.36 | 72.78 | -- | -- | -- | -- | 6,761,375.00 | -- | 3.96 | -- | 7.00 | 53.57 | 47.55 | 4.62 | 3.93 | -- | 4.08 | -- | 2.49 | 19.52 | 7.76 | 67.93 | 5.04 | 5.16 | -- |
